A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs ACH 4471 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Proof of concept; Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 10 Jul 2017 According to an Achillion Pharmaceuticals media release, the company plans to present the interim results of this study its second quarter 2017 results call.
- 06 Jun 2017 Planned number of patients changed from 4 to 12.
- 06 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 May 2018.